Fresh analysis indicates that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise plans.
Findings released in a leading health publication demonstrates that while overweight individuals can lose about a fifth of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying such treatments need to be cognizant of the danger of fast weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a return to starting mass within about 18 months.
Analyzing Approaches
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with other pills.
Scientists note that people who shed pounds through lifestyle changes alone usually have a slower creep back—approximately 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Experts suggest the way of the jabs is key to understanding the accelerated rebound.
These medications copy a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement results in hunger is no longer kept in check, making overeating a significant risk."
A Chronic Issue?
The NHS advise the injections for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the significant potential of relapse, the therapy is often long-term.
This opinion is echoed by drug manufacturers, who state that the results "emphasize the long-term character of obesity," similar to managing conditions like diabetes.
User Experiences
People who have discontinued the medication report a intense return of hunger.
"It was like a switch that goes on and I was suddenly ravenous," described a patient.
This challenge is worsened if users have not adopted permanent dietary or behavioural changes during treatment.
Growing Use
Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Use is greater among women than males.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while these medications are powerful tools for weight loss, they are not a permanent fix and long-term success relies on combined behavioural management.
